

March 12, 2024

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30(7) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to our disclosure dated March 6, 2024 in relation to the sale of 6,73,89,944 equity shares representing 55% of the issued and paid-up equity share capital of Glenmark Life Sciences Limited (“GLS”) from the Company to Nirma Limited (“Nirma”) pursuant to the share purchase agreement dated September 21, 2023 among the Company, Nirma and GLS. The transfer of remaining 2,45,05,435 equity shares representing 20% of the issued and paid-up equity share capital of GLS from the Company to Nirma has been completed, and closing under the share purchase agreement is now complete.

This is for your information and records.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer